A preliminary study of serum concentrations of soluble epidermal growth factor receptor (sErbB1), gonadotropins, and steroid hormones in healthy men and women

Cancer Epidemiology Biomarkers and Prevention

Volumn 10, Issue 11, 2001, Pages 1175-1185

  Baron, Andre T ^a   Lafky, Jacqueline M ^a   Maihle, Nita J ^a   Suman, Vera J ^b   Hillman, David W ^b   Buenafe, Marites C ^c   Boardman, Cecelia H ^d   Podratz, Karl C ^d   Perez, Edith A ^e  

^a MAYO CLINIC   (United States)

^b Cancer Center Statistics   (United States)

^c Departments of Medicine   (United States)

^d Division of Gynecologic Surgery   (United States)

^e MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ESTRADIOL; FOLLITROPIN; GONADOTROPIN; PROGESTERONE; STEROID HORMONE; TESTOSTERONE; TUMOR MARKER;

ADULT; AGE; AGED; ARTICLE; AUTOANALYZER; BLOOD ANALYSIS; CANCER; CONTROLLED STUDY; FEMALE; GENDER; GENE EXPRESSION REGULATION; GONADOTROPIN BLOOD LEVEL; HORMONAL REGULATION; HORMONE BLOOD LEVEL; HUMAN; IMMUNOASSAY; MALE; NORMAL HUMAN; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; PROTO ONCOGENE; STEROID BLOOD LEVEL;

ADULT; AGE FACTORS; AGED; BIOLOGICAL MARKERS; FEMALE; GONADAL STEROID HORMONES; GONADOTROPINS; HUMANS; LINEAR MODELS; MALE; MENOPAUSE; MIDDLE AGED; NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; REFERENCE VALUES; RISK FACTORS; SEX FACTORS;

EID: 0035161223     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (102)

1. Signalling by receptor tyrosine kinases
2. Neu and its ligands: From an oncogene to neural factors
3. Characterization of epidermal growth factor receptor gene expression in malignant and normal human cell lines
4. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
5. Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family: Evidence for overexpression in a subset of human mammary tumors
6. Overexpression of erbB-2 or EGF receptor proteins present in early stage mammary carcinoma is detected simultaneously in matched primary tumors and regional metastases
7. Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers
8. Overexpression of the c-erbB-2 oncoprotein: Why does this occur more frequently in ductal carcinoma in situ than in invasive mammary carcinoma and is this of prognostic significance?
9. Ligand-specific activation of HER4/p180erbB4, a fourth member of the epidermal growth factor receptor family
10. Epidermal growth factor-related peptides and their receptors in human malignancies
11. Expression of growth factors and their receptors in human early colorectal carcinomas: Immunohistochemical study
12. Prognostic significance of p53 and c-erbB-2 immunohistochemical evaluation in colorectal adenocarcinoma
13. c-erbB-2 oncoprotein in relation to DNA ploidy and prognosis in colorectal adenocarcinoma
14. Overexpression of c-erbB-2 mRNA and/or c-neu oncoprotein is a predictor for metastases from colorectal cancer
15. Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer
16. p185neu expression in human lung adenocarcinomas predicts shortened survival
17. Detection and increased amounts of the extracellular domain of the c-erbB-2 oncoprotein in serum during pulmonary carcinogenesis in humans
18. Prognostic significance of c-erbB-2 mRNA in ovarian carcinoma
19. Expression of c-erbB-2/neu proto-oncogene in human prostatic cancer tissues and cell lines
20. Prognostic value of c-erbB-2 and epidermal growth factor receptor in Stage I (Tla) prostatic adenocarcinoma
21. Epidermal-growth-factor receptors in human bladder cancer: Comparison of invasive and superficial tumours
22. The epidermal growth factor receptor and the prognosis of bladder cancer
23. Presence of epidermal growth factor receptor as an indicator of poor prognosis in patients with breast cancer
24. Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer
25. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
26. Epidermal growth factor receptors in non-small cell lung cancer
27. Epidermal growth factor receptor: A marker of early relapse in breast cancer and tumor stage progression in bladder cancer. Interactions with neu
28. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer
29. Overexpression of c-erbB-2 in epithelial ovarian cancer. Prognostic value and relationship with response to chemotherapy
30. Prognostic significance of serum c-erbB-2 protein in breast cancer patients
31. EGF-R expression in ductal breast cancer: Proliferation and prognostic implications
32. Prognostic importance of c-erbB-2 expression in breast cancer
33. Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer
34. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer
35. EGF/ErbB family receptors in ovarian cancer
36. The extracellular domain of p185/neu is released from the surface of human breast carcinoma cells. SK-BR-3
37. The extracellular domain of the c-erbB-2 oncoprotein is released from tumor cells by proteolytic cleavage
38. Expression cloning of human EGF receptor complementary DNA: Gene amplification and three related messenger RNA products in A431 cells
39. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells
40. Production of an epidermal growth factor receptor-related protein
41. Structure and localization of genes encoding aberrant and normal epidermal growth factor receptor RNAs from A431 human carcinoma cells
42. A truncated, secreted form of the epidermal growth factor receptor is encoded by an alternatively spliced transcript in normal rat tissue
43. Expression of epidermal growth factor receptors at the mRNA and cell membrane levels in first trimester and term human placentae
44. Possible role of variant RNA transcripts in the regulation of epidermal growth factor receptor expression in human placenta
45. Native avian c-erbB gene expresses a secreted protein product corresponding to the ligand-binding domain of the receptor
46. c-erbB3 gene encodes secreted as well as transmembrane receptor tyrosine kinase
47. A truncated intracellular HER2/neu receptor produced by alternative RNA processing affects growth of human carcinoma cells
48. Differential expression of epidermal growth factor receptor (EGF-R) gene and regulation of EGF-R bioactivity by progesterone and estrogen in the adult mouse uterus
49. A 1.8 kb alternative transcript from the human epidermal growth factor receptor gene encodes a truncated form of the receptor
50. Differential expression of the full-length and truncated forms of the epidermal growth factor receptor in the preimplantation mouse uterus and blastocyst
51. Isolation and characterization of four alternate c-erbB3 transcripts expressed in ovarian carcinoma derived cell lines and normal human tissues
52. Comparative genomic sequence analysis and isolation of human and mouse alternative EGFR transcripts encoding truncated receptor isoforms
53. A sandwich type acridinium-linked immunosorbent assay (ALISA) detects soluble ErbB1 (sErbB1) in normal human sera
54. Diagnostic utility of oncogenes and their products in human cancer
55. The c-erbB transmembrane growth factor receptors as serum biomarkers in human cancer studies
56. The detection of increased amounts of the extracellular domain of the epidermal growth factor receptor in serum during carcinogenesis in asbestosis patients
57. Serum levels of growth factor receptors, EGFR and Neu in asbestosis patients: A follow-up study
58. Epidermal growth factor receptor ectodomain in the urine of patients with squamous cell carcinoma
59. Detection of epidermal growth factor receptor in the serum of gastric carcinoma patients
60. Expression of a truncated epidermal growth factor receptor-like protein (TEGFR) in ovarian cancer
61. Serum sErbB1 and EGF levels as tumor biomarkers in women with stage III or IV epithelial ovarian cancer
62. In vitro and in vivo release of soluble erbB-2 protein in human carcinoma cells
63. Detection and quantitation of the human neu oncoprotein
64. Elevated soluble c-erbB-2 antigen levels in the serum and effusions of a proportion of breast cancer patients
65. Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer
66. Determination of a fragment of the c-erbB-2 translational product p185 in serum of breast cancer patients
67. Detection of the extracellular domain of c-erbB-2 oncoprotein in sera from patients with various carcinomas: Correlation with tumor markers
68. Elevated erbB-2 oncoprotein levels in preoperative and follow-up serum samples define an aggressive disease course in patients with breast cancer
69. c-erbB-2 oncoprotein, CEA, and CA 15.3 in patients with breast cancer: Prognostic value
70. Elevated serum levels of a c-erbB-2 oncogene product in ovarian cancer patients and in pregnancy
71. Prognostic significance of p105 (c-erbB-2, HER2/neu) serum levels in patients with ovarian cancer
72. Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein
73. Influence of circulating c-erbB-2 serum protein on response to adjuvant chemotherapy in node-positive breast cancer patients
74. Plasma c-erbB-2 levels in breast cancer patients: Prognostic significance in predicting response to chemotherapy
75. Hormonal regulation of type I receptor tyrosine kinase expression in the mammary gland
76. Estrogen suppression of erbB2 expression is associated with increased growth rate of ZR-75-1 human breast cancer cells in vitro and in nude mice
77. Antisense estrogen receptor RNA expression increases epidermal growth factor receptor gene expression in breast cancer cells
78. Inhibition of c-erbB-2 oncogene expression by estrogens in human breast cancer cells
79. Epidermal growth factor receptors in rat ovarian tissue
80. Hormonal treatment with sex steroids in women is associated with lower p105 serum concentrations
81. In vivo estrogen regulation of epidermal growth factor receptor in human endometrium
82. Menstrual cycle dependent variability for serum tumor markers CEA, AFP, CA 19-9, CA 125 and CA 15-3 in healthy women
83. The menopause transition
84. Menopause and the perimenopausal transition
85. Menopause issues for older women
86. Pituitary function
87. Physiology of reproduction
88. Increased serum concentrations of growth factor receptors and Neu in workers previously exposed to asbestos
89. Serum and correspondent tissue measurements of epidermal growth factor (EGF) and epidermal growth factor receptor (EGF-R). Clinical relevance in pancreatic cancer and chronic pancreatitis
90. Serum levels of pantropic p53 protein and EGF-receptor, and detection of anti-p53 antibodies in former uranium miners (SDAG Wismut)
91. p53 protein, EGF-receptor, and anti-p53 antibodies in serum from patients with occupationally derived lung cancer
92. A preliminary study of CA15-3, c-erbB2, epidermal growth factor receptor, cathepsin-D, and p53 in saliva among women with breast carcinoma
93. Quantitation of the extracellular domain of epidermal growth factor receptor in the plasma of dioxin-exposed individuals
94. Free, complexed and total serum prostate specific antigen: The establishment of appropriate reference ranges for their concentrations and ratios
95. Percent free prostate-specific antigen: Entering a new era in the detection of prostate cancer
96. Percentage of free prostate-specific antigen in sera predicts aggressiveness of prostate cancer a decade before diagnosis
97. Free to total prostatic specific antigen ratio as a new diagnostic tool in prostatic carcinoma
98. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease
99. Estimation of prostate cancer probability by logistic regression: Free and total prostate-specific antigen, digital rectal examination, and heredity are significant variables
100. Age-specific reference ranges for serum prostate-specific antigen in black men
101. Current thoughts on the detection of prostate cancer
102. Hormonal aspects of epithelial ovarian cancer: Review of epidemiological evidence